Know which one is about to reprice your market. Phontix AI tracks all three, and shows the source, the method and how much weight every number can bear.
Phontix AI is an AI-native intelligence platform. Every figure in it carries a named source, a documented method and a confidence tier.
Each takes a different market signal apart the same way: named sources where they exist, a documented method, a confidence tier on every figure, and the parts nobody can source left visibly empty.
Finds the exclusivity events worth developing for. Patent layers, regulatory exclusivity, challenge activity and a 2026 to 2035 opportunity forecast across the US, EU5 and India, with the source behind every entry.
For generic and biosimilar manufacturers choosing what to develop next, and for innovators planning around a patent cliff.
Price history, landed-cost build-up, demand and supply, and a forward view for chemicals across the petrochemical value chain. Every layer carries its basis, and you can change the assumptions yourself.
For procurement and category teams buying petrochemical-linked chemicals and polymers, especially mid-sized buyers who need to see how a price is built.
Reads reviews, marketplaces, video comments, forums and news, then turns what people say into themes, sentiment, share of voice and the places where sources disagree. Every reading carries its signal tier.
For brand, insights and e-commerce teams at CPG, FMCG and other consumer-facing brands.
Most intelligence products sell coverage. Buyers at this level rarely have a coverage problem. They have a trust problem: where did this number come from, what sits behind it, and will it hold up in front of a CFO?
Every Phontix AI output carries its method with it. Sources are named. Assumptions are visible. Forecasts trace back to the variables driving them. When our view changes, we record what changed and why.
Read the methodologyA generic opportunity estimate in LOE Edge is a chain, not a single model. Each stage is owned by one module, carries its own sources and uncertainty, and is read by the stages after it rather than recalculated.
Protection broken into its layers, because compound expiry is rarely the date a competitor can actually launch.
Built up from registry incidence and prevalence, filtered by subtype, stage and diagnosis.
Guideline eligibility narrowed to what is actually prescribed in that market.
Dosing, duration and unit price, with list and net prices kept apart.
Post-exclusivity erosion and share, split by how an entrant actually wins patients.
We list the sectors we actively serve, and say plainly how each product is available.
| Industry | Platform | Typical buyer | Availability |
|---|---|---|---|
| Pharma and life sciences | LOE Edge | Generic and biosimilar BD, portfolio selection, innovator lifecycle teams | Available now |
| Chemicals and materials | Price Fundamentals | Procurement, category management, commercial strategy | Available, scoped on request |
| Consumer brands | Brand Listener | Brand, insights, e-commerce and revenue management | Available, scoped on request |
Phontix AI is built by people who’ve done this work for Fortune 500 clients, not a general-purpose data team. We have spent our working lives delivering strategy and insight that went into sourcing, launch and investment decisions. That background decides what the platforms track. AI is what lets us track it at a depth and pace a manual research team can’t match.
Analysis from the categories we track. Every piece carries its method and sources.
Orange Book lists patent 9,539,218 on Xarelto 10, 15 and 20 mg to Feb 2034 (Aug 2034 with pediatric entry). FDA shows 19 approved generic applications.
US denosumab biosimilars entered from 2 June 2025 on reported settlement dates. Amgen's global Prolia sales fell 33% and Xgeva 31% in H1 2026.
In 2021 the Bristol Myers Squibb-Pfizer Alliance gave 1 April 2028 as the earliest US generic date, subject to appeals. The Orange Book lists other dates.
We run demos against your molecules, your feedstocks or your brands, not a canned dataset. Thirty minutes with an analyst.
